Condition: Takayasu Arteritis With Pulmonary Artery Involvement · Percutaneous Transluminal Pulmonary Angioplasty · PAH Targeted Medication · Sponsor: Chinese Pulmonary Vascular Disease Research Group
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
This description comes directly from the study's public registry record.
Zhihong Liu, doctor · 86-010-88396589 · zhihongliufuwai@163.com
Always discuss trial participation with your own doctor first.
| Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05388682